T1	Participants 39 72	patients with serious infections.
T2	Participants 240 329	consecutive patients with serious infections for whom an aminoglycoside seemed warranted.
T3	Participants 330 402	Exclusion criteria were neutropenia or severely impaired renal function.
T4	Participants 403 430	123 patients were enrolled.
T5	Participants 431 700	For efficacy analysis only those patients were considered in whom treatment with the aminoglycoside was not stopped within 72 h (n = 67); toxicity was analysed on patients receiving aminoglycosides for more than 48 h and not using other nephrotoxic medication (n = 85).
T6	Participants 939 993	Baseline characteristics were comparable in both arms.
